<SEC-DOCUMENT>0001213900-20-036675-index.html : 20201113
<SEC-HEADER>0001213900-20-036675.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201112191948
ACCESSION NUMBER:		0001213900-20-036675
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-236797
		FILM NUMBER:		201308614

	BUSINESS ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-79-779-60-00

	MAIL ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>ea129645-f1a3_nlspharma.htm
<DESCRIPTION>AMENDMENT NO. 3 TO FORM F-1
<TEXT>
Document 1 - file: ea129645-f1a3_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea129645ex1-1_nlspharma.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT BY AND AMONG NLS PHARMACEUTICS LTD. AND THE UNDERWRITERS NAMED THEREIN
<TEXT>
Document 2 - file: ea129645ex1-1_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ea129645ex4-2_nlspharma.htm
<DESCRIPTION>FORM OF WARRANT AGENT AGREEMENT
<TEXT>
Document 3 - file: ea129645ex4-2_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ea129645ex4-3_nlspharma.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
Document 4 - file: ea129645ex4-3_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ea129645ex5-1_nlspharma.htm
<DESCRIPTION>OPINION OF WENGER & VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD
<TEXT>
Document 5 - file: ea129645ex5-1_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>6
<FILENAME>ea129645ex5-2_nlspharma.htm
<DESCRIPTION>OPINION OF SULLIVAN & WORCESTER LLP, U.S. COUNSEL TO NLS PHARMACEUTICS LTD
<TEXT>
Document 6 - file: ea129645ex5-2_nlspharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 7 - file: ex5-1_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: ex5-1_002.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex5-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 9 - file: ex5-2_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex5-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 10 - file: ex5-2_002.jpg

</DOCUMENT>
</SEC-DOCUMENT>